Clinical Report: FDA’s Black Box Change for Hormone Replacement Therapy Drugs

Overview

Revise to specify that the FDA's decision reflects evolving evidence rather than a definitive conclusion about risks.

Background

The FDA's previous black box warning on HRT was implemented due to concerns raised by the Women’s Health Initiative study, which linked HRT to increased risks of breast cancer and cardiovascular events. This warning has contributed to a stigma surrounding HRT, leading to decreased usage among women who could benefit from treatment for menopause symptoms. The recent change aims to facilitate more open discussions about menopause management and HRT options.

Data Highlights

No specific numerical data was provided in the source material.

Key Findings

• The FDA has removed warnings related to cardiovascular disease, breast cancer, and probable dementia from HRT labels.
• Women starting HRT before age 60 may have a decreased mortality risk.
• Recent meta-analyses indicate that HRT use is not associated with increased cancer mortality.
• Localized vaginal HRT does not increase breast cancer risk, even in women with a history of hormone-sensitive cancers.
• Individualized assessment of risks and benefits is crucial for HRT therapy.

Clinical Implications

Highlight the necessity of individualized assessments and shared decision-making.

Conclusion

The FDA's decision to remove the black box warning on HRT represents a significant shift in the management of menopause symptoms, encouraging healthcare professionals to reevaluate treatment options for their patients.

References

1. ASCO Statement, The ASCO Post, 2025 -- HHS Revision of Black Box Warning for Hormone Replacement Therapy and its Implications for Cancer Care
2. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, The ASCO Post, 2026 -- FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
3. Rethinking Menopause Hormone Therapy, Conexiant -- Rethinking Menopause Hormone Therapy
4. FDA removing warning from hormone-based menopause drugs, Associated Press Health -- FDA removing warning from hormone-based menopause drugs
5. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality, JAMA Network -- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials
6. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
7. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials | Breast Cancer | JAMA | JAMA Network